Ralliant Corporation (NYSE:RAL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Ralliant Corporation (NYSE:RAL) have been assigned a consensus rating of “Moderate Buy” from the twelve research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $75.70.

RAL has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Morgan Stanley lifted their price objective on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 23rd. Wall Street Zen downgraded shares of Ralliant from a “buy” rating to a “hold” rating in a report on Sunday, July 26th. Royal Bank Of Canada upped their target price on shares of Ralliant from $71.00 to $73.00 and gave the company a “sector perform” rating in a research report on Friday. Finally, Oppenheimer increased their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

Hedge Funds Weigh In On Ralliant

A number of institutional investors and hedge funds have recently modified their holdings of RAL. Nolet Wealth Management LLC bought a new position in shares of Ralliant during the 2nd quarter valued at approximately $280,000. Wasatch Advisors LP purchased a new stake in Ralliant during the 2nd quarter valued at $40,526,000. Mirador Capital Partners LP bought a new stake in Ralliant in the second quarter worth $227,000. GAMMA Investing LLC lifted its position in Ralliant by 42.8% in the second quarter. GAMMA Investing LLC now owns 1,274 shares of the company’s stock worth $94,000 after buying an additional 382 shares during the last quarter. Finally, Versant Capital Management Inc boosted its stake in Ralliant by 230.1% during the second quarter. Versant Capital Management Inc now owns 604 shares of the company’s stock worth $44,000 after buying an additional 421 shares during the period.

Ralliant Stock Performance

NYSE:RAL opened at $65.78 on Friday. The company has a market cap of $7.36 billion and a price-to-earnings ratio of -6.06. Ralliant has a 1 year low of $37.27 and a 1 year high of $75.41. The stock’s 50 day simple moving average is $67.20 and its two-hundred day simple moving average is $54.34. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.05.

Ralliant (NYSE:RAL) last posted its earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The firm had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, equities analysts anticipate that Ralliant will post 2.83 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio is -1.83%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.